To determine whether the observation that 5-FU treatment selectively enriches CD133+ colon cancer cells in vitro can be extended to human colon cancer patients, colon carcinoma tissues from human patients with and without prior 5-FU therapies were stained with CD133-specific antibodies and analyzed for CD133 protein expression. This evidence concerns the gene PROM1 and colonic neoplasm.